Pivotal Response Treatment for Individuals With Intellectual Disabilities

Sponsor
Stanford University (Other)
Overall Status
Completed
CT.gov ID
NCT01988623
Collaborator
(none)
21
1
1
60.6
0.3

Study Details

Study Description

Brief Summary

The investigators will assess the efficacy of Pivotal Response Treatment (PRT) in the treatment of communication deficits in children with intellectual disabilities. By collecting information about parent and child functioning before and after PRT, The investigators will be able to determine whether the intervention is effective in improving child communication and reducing parent stress.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Pivotal Response Treatment (PRT)
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
21 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Pivotal Response Treatment for Individuals With Intellectual Disabilities
Study Start Date :
Sep 11, 2012
Actual Primary Completion Date :
Sep 30, 2017
Actual Study Completion Date :
Sep 30, 2017

Arms and Interventions

Arm Intervention/Treatment
Experimental: Pivotal Response Treatment (PRT)

Behavioral: Pivotal Response Treatment (PRT)

Outcome Measures

Primary Outcome Measures

  1. Change from Baseline on the MacArthur-Bates Communication Development Inventory at 6, 12, and 24 weeks [6, 12 and 24 weeks]

  2. Change from Baseline in communication during parent-child and clinician-child interactions at 6, 12, and 24 weeks [6, 12 and 24 weeks]

  3. Change from Baseline on the Social Responsiveness Scale (SRS) at 6, 12, and 24 weeks [6, 12 and 24 weeks]

  4. Change from Baseline on the Clinical Global Impression Scale at 6, 12, and 24 weeks [6, 12, and 24 weeks]

Secondary Outcome Measures

  1. Change from Baseline on the Vineland Adaptive Behavior Scales, Second Edition (VABS-II) at 6, 12, and 24 weeks [6, 12 and 24 weeks]

  2. Change from Baseline on the Parenting Stress Index (PSI) at 6, 12, and 24 weeks [6, 12, and 24 weeks]

  3. Change from Baseline on the Family Empowerment Scale (FES) at 6, 12, and 24 weeks [6, 12, and 24 weeks]

Eligibility Criteria

Criteria

Ages Eligible for Study:
2 Years to 17 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria for Individuals with Intellectual Disabilities:
  • Participants will have an age range between 2 and 17.11 years of age inclusive

  • Male or female

  • Diagnosis of an intellectual disability based on the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR), the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10), and an expert clinical evaluation

  • have historical evidence of significant abnormal developmental milestones as determined by neurological history

  • care provider that will reliably bring subject to study visits, and is trustworthy to provide accurate accounts of services provided to the subject

Inclusion Criteria for Individuals with Speech Delay/Language Disorder:
  • Participants will have an age range between 2 and 17.11 years of age inclusive

  • Male or female

  • Diagnosis of a speech delay based on the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR), the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10), and an expert clinical evaluation

  • Preschool Language scale (PLS) score of at least 1 standard deviations below age level (for children in the age range of 2-6.11)

  • care provider that will reliably bring subject to study visits, and is trustworthy to provide accurate accounts of services provided to the subject

Exclusion Criteria:
  • medically unstable (such as having unstable seizures)

  • primary diagnosis of Autism Spectrum Disorder (ASD) is exclusionary as determined by the investigators

Contacts and Locations

Locations

Site City State Country Postal Code
1 Stanford University School of Medicine Stanford California United States 94305-5719

Sponsors and Collaborators

  • Stanford University

Investigators

  • Principal Investigator: Antonio Y. Hardan, M.D., Stanford University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Antonio Hardan, Professor of Psychiatry and Behavioral Sciences, Stanford University
ClinicalTrials.gov Identifier:
NCT01988623
Other Study ID Numbers:
  • IRB-25229
First Posted:
Nov 20, 2013
Last Update Posted:
Jan 12, 2021
Last Verified:
Jan 1, 2021
Keywords provided by Antonio Hardan, Professor of Psychiatry and Behavioral Sciences, Stanford University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 12, 2021